Search the Newsreel

Carter's Gains 19.4% in 3 Months as Growth Momentum Supports Upside Case

Carter's, Inc. CRI shares have gained 19.4% over the past three months, outperforming the industry as improving retail trends, international growth and productivity initiatives support the business. The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's …

Maplebear (NASDAQ:CART) Given New $58.00 Price Target at Citigroup

Citigroup has raised its price target for Maplebear (NASDAQ:CART) to $58.00 from $50.00, maintaining a "buy" rating and implying a 16.72% upside. This follows a trend of positive analyst sentiment, with several firms recently increasing their targets for the stock. Despite missing earnings per …

Descartes Systems Group Stock Surges 1.95% as Logistics Software, AI and Global Trade Digitization Support Growth

Descartes Systems Group Inc. (TSX:DSG) saw its stock rise by 1.95% due to renewed investor interest in its logistics and supply-chain software. The company benefits from the increasing complexity of global trade, e-commerce growth, and the integration of AI in logistics, offering mission-critical solutions …

Cartesian Therapeutics Advances RNA Cell Therapy Pipeline; Wedbush Sets $38 Price Target

Cartesian Therapeutics (RNAC) is advancing its RNA cell therapy pipeline, with its lead candidate, Descartes-08, an autologous RNA CAR-T therapy, holding significant potential for autoimmune diseases. Wedbush has set a price target of $38 for the company. The therapy has received FDA RMAT, Fast …

The Descartes Systems Group Inc.

U.S. container imports in July reached the fourth-highest level on record, according to supply chain technology provider Descartes Systems Group. Shippers increased imports in anticipation of potential U.S. tariff changes. This data highlights significant activity in global trade and logistics.

Descartes Systems Group Inc (DSGX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Maplebear Inc (CART) Earnings Forecast: Future EPS & Revenue Growth Estimates

Maplebear (CART) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

CART Q2 Deep Dive: Customer Growth and Expanding Enterprise Partnerships

CART Q2 Deep Dive: Customer Growth and Expanding Enterprise Partnerships Online grocery delivery platform Instacart (NASDAQ:CART) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 14.1% year on year to $1.04 billion. Its GAAP profit of $0.45 per share was …

Cartesian Therapeutics (NASDAQ:RNAC) Announces Quarterly Earnings Results

Cartesian Therapeutics (NASDAQ:RNAC) announced its quarterly earnings, reporting an EPS of $0.46, significantly beating the consensus estimate of a $0.88 loss. Following the announcement, RNAC shares rose 1.0% to $8.85, with analysts maintaining a "Moderate Buy" rating and an average price target of $32.60. …

Why Maplebear (CART) Is Up 12.5% After Q2 Profit Jump And UK AI Trolley Expansion

Maplebear Inc. (Instacart) reported strong Q2 2026 results with sales of US$1,043 million and net income of US$111 million, alongside an extensive share repurchase program. The company also expanded its AI-powered Caper smart trolleys into the UK with Morrisons, indicating a strategic shift towards …

Why Is Maplebear (CART) Pushing Further Into Europe Through A New Partnership?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Maplebear (NasdaqGS:CART) company Instaleap has entered a partnership with SPAR Slovenia to power the retailer's e-commerce fulfillment operations in continental Europe. The agreement …

Arrowstreet Capital Limited Partnership Decreases Stock Holdings in Carter Bankshares, Inc. $CARE

Arrowstreet Capital Limited Partnership significantly reduced its stake in Carter Bankshares, Inc. (NASDAQ:CARE) by 75.2% in the first quarter, now holding 11,601 shares valued at $271,000. Other institutional investors have also adjusted their positions in the company. Carter Bankshares reported disappointing Q1 earnings, missing …

A Quick Look at Today's Ratings for Cartesian Therapeutics(RNAC.US), With a Forecast Between $25 to $44

This article provides an overview of recent analyst ratings for Cartesian Therapeutics (RNAC.US), highlighting a price target forecast ranging from $25 to $44. It indicates that the company has received a "Strong Buy" consensus from analysts, based on positive evaluations over the past three …

Cartesian Therapeutics (NASDAQ:RNAC) Upgraded by Wall Street Zen to Hold Rating

Cartesian Therapeutics (NASDAQ:RNAC) was upgraded by Wall Street Zen from a "sell" to a "hold" rating. Despite this upgrade, the company still holds a "Moderate Buy" consensus rating among analysts with an average price target of $32.60. Institutional investors own a significant portion of …

Maplebear Inc. Stock 12‑Month Price Target Raised to $57.11, Implies 27% Upside

Analysts have raised the 12-month price target for Maplebear Inc. stock to $57.11 from $52.15, implying a potential upside of approximately 27% based on its August 6 closing price. This new target is derived from the estimates of 27 analysts, with forecasts ranging from …

Carter's (CRI) Posts Stronger Earnings And New Guidance, Is It Still Below Fair Value?

Carter Bankshares (NASDAQ:CARE) Lowered to "Hold" Rating by Wall Street Zen

Wall Street Zen has downgraded Carter Bankshares (NASDAQ:CARE) to a "Hold" rating from "Buy," aligning with the majority of analysts who also rate the stock as "Hold." This downgrade follows the company's recent earnings report, which significantly missed consensus estimates for both EPS and …

Maplebear (NASDAQ:CART) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen has downgraded Maplebear (NASDAQ:CART) from a "buy" to a "hold" rating, despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $55.14. The company reported strong Q2 revenue of $1.04 billion, exceeding estimates, but missed earnings …

Maplebear (NASDAQ:CART) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Maplebear (NASDAQ:CART) released its quarterly earnings, reporting an EPS of $0.45, which missed analysts' consensus estimates by $0.09, despite exceeding revenue expectations with $1.04 billion, a 14.1% year-over-year increase. The company showed strong operational performance with adjusted EBITDA up 19% and free cash flow …

Carter's (CRI) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer and President - Sharon Price JohnChief Financial Officer and Chief Operating Officer - Richard WestenbergerChief Retail and Digital Officer - Allison PetersonVice President, Investor Relations …

Instacart (CART) Stock Climbs As Ad Growth Fuels Cash Rich Quarter

Instacart (Maplebear) stock climbed over 11% after its Q2 2026 earnings report, which showed solid revenue and net income. The company's growth is driven by advertising and AI initiatives, leading to strong free cash flow and share buybacks. However, concerns remain regarding margin pressure, …

Descartes Systems Group Inc (DSGX) Stock News Today

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. announced the granting of inducement awards to four new employees, consisting of options to purchase 115,250 shares of the Company’s common stock. These options have an exercise price equal to the closing trading price on their respective grant dates of August …

Four new employees get options for 115,250 Cartesian shares

Cartesian Therapeutics (NASDAQ: RNAC) has granted stock options for an aggregate of 115,250 common shares to four new employees, with grant dates of August 3 and August 6, 2026. These options have an exercise price equal to the closing Nasdaq Global Market price on …

Cartesian Therapeutics 2Q Research and Development Expenses $20.4M >RNAC

Cartesian Therapeutics reported research and development expenses of $20.4 million for the second quarter. This financial detail is a key indicator of the company's investment in its pipeline and future growth. The article focuses solely on this financial reporting without further elaboration.

Maplebear (CART) insider Chris Rogers files to sell 4,933 shares after prior sale

Maplebear Inc. insider Chris Rogers has filed a Form 144 notice to sell up to 4,933 shares of common stock, which originated from a restricted stock lapse on May 15, 2026. This planned sale follows a previous transaction on June 1, 2026, where Rogers …

Carter's Q1 Earnings on The Horizon: What Should Investors Know?

Carter's (CRI) is set to report its first-quarter 2026 earnings, with analysts expecting top-line growth but a decline in the bottom line. Despite facing a challenging retail landscape and rising SG&A expenses, the company is projected to benefit from strong brand recognition, strategic investments …

Why Instacart Stock Popped Today

Shares of Maplebear (NASDAQ: CART), the company better known as Instacart, were moving higher today after the company topped revenue estimates in the second quarter and issued a strong outlook. As of 11:05 a.m. ET, the stock was up 11.9% on the news. Missed …

Instacart's AI assistant: If they build it, bigger baskets will come

[Instacart company closeup sign is seen in Toronto, Canada.] JHVEPhoto Driven by advertising gains and higher order values, Instacart (CART [https://seekingalpha.com/symbol/CART]) beat Wall Street’s expectations for the second quarter [https://seekingalpha.com/news/4628285-instacarts-core-business-delivers-double-digit-gtv-revenue-growth-eps-misses] and set its third quarter guidance to reflect the gains in the business during …

CART Q2 Earnings Miss, Revenues Beat on GTV and Ad Growth

Maplebear Inc. CART, doing business as Instacart, delivered mixed second-quarter 2026 results, with earnings falling short of the Zacks Consensus Estimate, while revenues surpassed expectations. The grocery technology company continued to benefit from robust Gross Transaction Value ("GTV") growth, expanding customer engagement and strength …

Maplebear Inc. 2026: Revenue $1.04B, EPS $0.45— 10-Q Summary

Maplebear Inc. reported strong second-quarter 2026 results, with revenue reaching $1.04 billion, a 14.1% increase year-over-year, and diluted EPS growing to $0.45. This growth was driven by a 14% rise in gross transaction value and increased advertising revenue, while net income slightly decreased to …

Cartesian Therapeutics Inc (RNAC) Stock News Today

Carter Bankshares, Inc. Q2 2026: Revenue $61.5M, Net income $28.9M, EPS $1.31— 10-Q Summary

Carter Bankshares, Inc. reported strong financial results for Q2 2026, with revenue of $61.5M, net income of $28.9M, and diluted EPS of $1.31, all showing significant year-over-year increases. These improvements were driven by higher net interest income, margin expansion, and strategic portfolio actions. The …

Maplebear Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CART) 2026-08-07

Maplebear Inc. (NASDAQ:CART) released its Q2 2026 earnings call presentation, reporting an EPS of $0.87, which missed estimates by $0.10. The company's revenue reached $1.04 billion, beating expectations by $16.76 million with a 14.11% year-over-year increase. The slide deck was published in conjunction with …

Carter Bankshares Inc (CARE) Stock News Today

This article from TradingKey provides current information for Carter Bankshares Inc (CARE) stock. It includes the stock's current price and daily performance, market capitalization, and P/E ratio. The article notes that more news, earnings, and analyst ratings will be available soon.

Carter Bankshares Inc (CARE) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Carter Bankshares Inc (CARE), highlighting its current earnings forecast score of 6.50 within the Banking Services industry. It details analyst ratings, target prices, and expected future EPS and revenue figures. The consensus among 5 analysts points to …